Y

Yashoda Hospital | Clinical Research Department

Research site
(Unclaimed)
Location
Raj Bhavan Road, Somajiguda, Hyderabad, Telangana, India
Site insights

Top conditions

Breast Cancer (4 trials)

Multiple Myeloma (3 trials)

Lung Cancer (3 trials)

Plasma Cell Cancer (3 trials)

Non-Small-Cell Lung Carcinoma (3 trials)

Top treatments

Dexamethasone
Carfilzomib
Hydroxyurea
Lyrica
Methylprednisolone
Cytarabine
Paclitaxel
Azacitidine
Dacomitinib
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 21
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib
Locations recently updated

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Enrolling
Neoplasm Metastasis
Breast Neoplasms
Drug: Exemestane
Drug: Imlunestrant

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Carfilzomib

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Placebo
Drug: Asundexian (BAY2433334)

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS...

Active, not recruiting
Acute Myeloid Leukemia
Biological: Galinpepimut-S
Drug: Azacitidine

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod
Other: Placebo

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Enrolling
Sickle Cell Disease
Drug: NDec - oral decitabine-tetrahydrouridine
Drug: HU - Hydroxyurea

To characterize safety associated with the use of Kyprolis under the locally approved label.

Active, not recruiting
Relapsed Refractory Multiple Myeloma
Drug: Drug: Carfilzomib + Dexamethasone
Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone

Trial sponsors

Roche logo

Roche (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems